Zhaoyang Teng
YOU?
Author Swipe
View article: Neuroprotective properties of extra virgin olive oil polyphenols in Alzheimer’s disease: a multi-target mechanistic review
Neuroprotective properties of extra virgin olive oil polyphenols in Alzheimer’s disease: a multi-target mechanistic review Open
Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by β-amyloid (Aβ) deposition, hyperphosphorylated tau protein, neuroinflammation, and mitochondrial dysfunction. The limited efficacy of single-target pharmacol…
View article: Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma
Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma Open
Background: Quantitative drug benefit–risk assessment (BRA) helps assess the magnitude of benefit and risk of new cancer therapies. This BRA aimed to summarize the evidence for the benefits and risks of ivosidenib versus placebo for the tr…
View article: Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint
Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint Open
In clinical trials with time‐to‐event data, the evaluation of treatment efficacy can be a long and complex process, especially when considering long‐term primary endpoints. Using surrogate endpoints to correlate the primary endpoint has be…
View article: Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe
Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe Open
Background Real-world data on treatment patterns/outcomes for metastatic pancreatic cancer (mPAC) are limited. This study aims to assess real-world treatment patterns, survival outcomes, and prognostic/predictive factors in patients with m…
View article: Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial Open
Background Nanoliposomal irinotecan (nal-IRI) was recently authorized in Japan for unresectable pancreatic cancer after disease progression following chemotherapy. Physicians now consider certain aspects of nal-IRI safety profile as slight…
View article: Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma Open
View article: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma Open
View article: Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma Open
In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. …
View article: PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST‐AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION‐FREE SURVIVAL – ANALYSIS FROM THE TOURMALINE‐MM3 STUDY
PS1382 DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST‐AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION‐FREE SURVIVAL – ANALYSIS FROM THE TOURMALINE‐MM3 STUDY Open
Background: Deepened response has been associated with prolonged progression‐free (PFS) and overall survival in multiple myeloma, including in the maintenance therapy setting. In the Myeloma XI trial, post‐ASCT maintenance with lenalidomid…
View article: Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial Open
View article: Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma
Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma Open
Summary There is a need for efficacious, convenient treatments with long‐term tolerability for patients with relapsed/refractory multiple myeloma ( RRMM ). This phase 2 study evaluated the all‐oral combination of ixazomib, cyclophosphamide…
View article: Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor Open
Model‐informed drug development (MIDD) was central to the development of the oral proteasome inhibitor ixazomib, facilitating internal decisions (switch from body surface area (BSA)‐based to fixed dosing, inclusive phase III trials, portfo…
View article: Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development
Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development Open
The failure rate for phase III trials in oncology is high; quantitative predictive approaches are needed. We developed a model‐based meta‐analysis (MBMA) framework to predict progression‐free survival (PFS) from overall response rates (ORR…
View article: Prospective Relation of Circulating Adipokines to Incident Metabolic Syndrome: The Framingham Heart Study
Prospective Relation of Circulating Adipokines to Incident Metabolic Syndrome: The Framingham Heart Study Open
Background Adipokines are elaborated by adipose tissue and are associated with glycemic, lipid, and vascular traits. We hypothesized that in a cross‐sectional analysis circulating adipokines are altered among subsets of obesity stratified …
View article: Optimal and adaptive designs for multi-regional clinical trials with regional consistency requirement
Optimal and adaptive designs for multi-regional clinical trials with regional consistency requirement Open
To shorten the time for drug development and regulatory approval, a growing number of clinical trials are being conducted in multiple regions simultaneously. One of the challenges to multi-regional clinical trials (MRCT) is how to utilize …